Abstract
Aim: Comparison of clinical outcomes of nivolumab + ipilimumab versus BRAF + MEK inhibitors (dabrafenib + trametinib or vemurafenib + cobimetinib) in ......
小提示:本篇文献需要登录阅读全文,点击跳转登录